Literature DB >> 18636638

Genetic counseling for the 22q11.2 deletion.

Donna M McDonald-McGinn1, Elaine H Zackai.   

Abstract

Because of advances in palliative medical care, children with the 22q11.2 deletion syndrome are surviving into adulthood. An increase in reproductive fitness will likely follow necessitating enhanced access to genetic counseling for these patients and their families. Primary care physicians/obstetric practitioners are in a unique position to identify previously undiagnosed patients as they reach reproductive age and to refer them for genetic counseling. To date, most deletions are de novo, secondary to homologous recombination between low-copy repeat sequences located within 22q11.2. Nonetheless, both somatic and germ line mosaicism has been observed giving unaffected parents a small risk of recurrence. Once present though there is a 50% chance for a person with this contiguous deletion to have an affected child. With this in mind, a variety of prenatal monitoring techniques, as well as, preimplantation genetic diagnosis are available depending on the specific level of risk.

Entities:  

Mesh:

Year:  2008        PMID: 18636638     DOI: 10.1002/ddrr.10

Source DB:  PubMed          Journal:  Dev Disabil Res Rev        ISSN: 1940-5529


  24 in total

Review 1.  Genomic copy number variation in disorders of cognitive development.

Authors:  Eric M Morrow
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-11       Impact factor: 8.829

2.  Practical guidelines for managing patients with 22q11.2 deletion syndrome.

Authors:  Anne S Bassett; Donna M McDonald-McGinn; Koen Devriendt; Maria Cristina Digilio; Paula Goldenberg; Alex Habel; Bruno Marino; Solveig Oskarsdottir; Nicole Philip; Kathleen Sullivan; Ann Swillen; Jacob Vorstman
Journal:  J Pediatr       Date:  2011-05-12       Impact factor: 4.406

3.  Assessment of parental disclosure of a 22q11.2 deletion syndrome diagnosis and implications for clinicians.

Authors:  Dana Faux; Kelly Schoch; Sonja Eubanks; Stephen R Hooper; Vandana Shashi
Journal:  J Genet Couns       Date:  2012-08-31       Impact factor: 2.537

4.  Acceptance and commitment therapy in genetic counselling: a case study of recurrent worry.

Authors:  Stephanie Broley
Journal:  J Genet Couns       Date:  2012-12-14       Impact factor: 2.537

5.  Behavior, brain, and genome in genomic disorders: finding the correspondences.

Authors:  Elena L Grigorenko; Alexander E Urban; Einar Mencl
Journal:  J Dev Behav Pediatr       Date:  2010-09       Impact factor: 2.225

6.  Genetic counseling, activism and 'genotype-first' diagnosis of developmental disorders.

Authors:  Daniel Navon
Journal:  J Genet Couns       Date:  2012-07-21       Impact factor: 2.537

Review 7.  Congenital heart diseases and cardiovascular abnormalities in 22q11.2 deletion syndrome: From well-established knowledge to new frontiers.

Authors:  Marta Unolt; Paolo Versacci; Silvia Anaclerio; Caterina Lambiase; Giulio Calcagni; Matteo Trezzi; Adriano Carotti; Terrence Blaine Crowley; Elaine H Zackai; Elizabeth Goldmuntz; James William Gaynor; Maria Cristina Digilio; Donna M McDonald-McGinn; Bruno Marino
Journal:  Am J Med Genet A       Date:  2018-04-16       Impact factor: 2.802

8.  Genetic counseling in the adult with congenital heart disease: what is the role?

Authors:  Luke Burchill; Steven Greenway; Candice K Silversides; Seema Mital
Journal:  Curr Cardiol Rep       Date:  2011-08       Impact factor: 2.931

9.  Schizophrenia Spectrum Disorders in a Danish 22q11.2 Deletion Syndrome Cohort Compared to the Total Danish Population--A Nationwide Register Study.

Authors:  Anders Vangkilde; Line Olsen; Louise K Hoeffding; Carsten B Pedersen; Preben B Mortensen; Thomas Werge; Betina Trabjerg
Journal:  Schizophr Bull       Date:  2016-01-05       Impact factor: 9.306

10.  22q11.2 deletions in patients with conotruncal defects: data from 1,610 consecutive cases.

Authors:  Shabnam Peyvandi; Philip J Lupo; Jennifer Garbarini; Stacy Woyciechowski; Sharon Edman; Beverly S Emanuel; Laura E Mitchell; Elizabeth Goldmuntz
Journal:  Pediatr Cardiol       Date:  2013-04-21       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.